These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16428490)

  • 21. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
    Gates JD; Carmichael MG; Benavides LC; Holmes JP; Hueman MT; Woll MM; Ioannides CG; Robson CH; McLeod DG; Ponniah S; Peoples GE
    J Am Coll Surg; 2009 Feb; 208(2):193-201. PubMed ID: 19228530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Benavides LC; Gates JD; Carmichael MG; Patil R; Holmes JP; Hueman MT; Mittendorf EA; Craig D; Stojadinovic A; Ponniah S; Peoples GE
    Clin Cancer Res; 2009 Apr; 15(8):2895-904. PubMed ID: 19351776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
    Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
    Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer.
    Mittendorf EA; Gurney JM; Storrer CE; Shriver CD; Ponniah S; Peoples GE
    Surgery; 2006 Mar; 139(3):407-18. PubMed ID: 16546506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
    Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
    Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
    Holmes JP; Clifton GT; Patil R; Benavides LC; Gates JD; Stojadinovic A; Mittendorf EA; Ponniah S; Peoples GE
    Cancer; 2011 Feb; 117(3):463-71. PubMed ID: 20845479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
    Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
    Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
    Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer.
    Kuerer HM; Thompson PA; Krishnamurthy S; Fritsche HA; Marcy SM; Babiera GV; Singletary SE; Cristofanilli M; Sneige N; Hunt KK
    Clin Cancer Res; 2003 Feb; 9(2):601-5. PubMed ID: 12576424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
    Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
    Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
    Woll MM; Hueman MT; Ryan GB; Ioannides CG; Henderson CG; Sesterhan IA; Shrivasta S; McLeod DG; Moul JW; Peoples GE
    Int J Oncol; 2004 Dec; 25(6):1769-80. PubMed ID: 15547716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer.
    Schippinger W; Dandachi N; Regitnig P; Hofmann G; Balic M; Neumann R; Samonigg H; Bauernhofer T
    Am J Clin Pathol; 2007 Oct; 128(4):630-7. PubMed ID: 17875515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
    Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
    Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
    Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.
    Hefler L; Tempfer C; Heinze G; Mayerhofer K; Breitenecker G; Leodolter S; Reinthaller A; Kainz C
    Br J Cancer; 1999 Nov; 81(5):855-9. PubMed ID: 10555758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.
    Tokatli F; Altaner S; Uzal C; Ture M; Kocak Z; Uygun K; Bilgi S
    Exp Oncol; 2005 Jun; 27(2):145-9. PubMed ID: 15995634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.